Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer, named for its lipid- and glycogen-rich “clear” cells. This distinct metabolic phenotype involves the accumulation of specific lipids (e.g., cholesterol esters) not seen in other RCC subtypes.
However, the clinical significance of ccRCC’s altered lipid metabolism has remained unclear. ccRCC tumors often exhibit dense immune cell infiltration, particularly by T cells. Interestingly, high T cell infiltration does not correlate with better outcomes of ccRCC patients, as opposed to some other tumor entities. These observations raise the question of how metabolic reprogramming in ccRCC might influence tumor behavior and anti-tumor immunity.
Key Findings
In our study, we profiled ccRCC tumors and normal kidney tissue to investigate lipid metabolism and its relationship to patient survival and immune context. Major findings include:
- Prognostic Metabolic Signature: We identified a gene-expression signature of lipid metabolism that stratified patients by survival. Clustering tumors by high expression of fatty acid degradation and cholesterol biosynthesis genes defined a subgroup with significantly better overall survival. This metabolic clustering was specific to ccRCC (not observed in papillary RCC) and remained prognostically independent of traditional factors like tumor size or stage.
- Oleate-Rich Lipid Accumulation: ccRCC tumors showed enhanced lipid accumulation, notably of oleate-containing species (such as cholesteryl oleate). We found that extracellular fluid from tumor cores was enriched in oleate-related lipids, and tumors with higher levels of these lipids tended to have lower CD8 T cell infiltration.
- Impact on T cell Function: Functionally, we observed that exposing ccRCC-infiltrating T cells to oleate impaired their activity. Oleate treatment suppressed CD8 T cells in vitro. This finding suggests that lipid accumulation in ccRCC can actively dampen the local immune response. Taken together, our data indicate that dysregulated lipid metabolism in ccRCC is prognostically relevant and can shape the intratumoral immune landscape.
Our results have several implications for clinical practice in urologic oncology. First, the lipid metabolism gene signature could serve as a novel prognostic biomarker for ccRCC. This molecular stratification, being independent of tumor grade or size, might help identify patients at higher risk of progression who could benefit from closer monitoring or adjuvant therapy. Secondly, the link between tumor lipids and immune cell function provides insight into ccRCC’s variable response to immunotherapy. An immunosuppressive metabolic microenvironment (rich in oleate and related lipids) may explain why some tumors with abundant T cells still fare poorly. In the future, assessing a tumor’s metabolic profile might inform treatment decisions – for example, flagging patients whose tumors could be less responsive to immune checkpoint inhibitors alone. While speculative, these findings also open the door to research on targeting lipid metabolism as an adjunct strategy: modulating fatty acid pathways might reinvigorate T-cell activity and improve responses to immunotherapies. We caution that therapeutic applications are not proven, but the prospect of altering tumor metabolism to enhance anti-tumor immunity in ccRCC is an intriguing avenue for further clinical research.
Conclusion
In summary, we demonstrate that altered lipid metabolism in cc RCC is an important predictor of patient survival and a determinant of the tumor’s immune milieu. Accumulation of oleate-rich lipids emerges as a central feature associated with worse outcomes and suppressed CD8 T cell response. These findings highlight lipid metabolic profiling as a promising tool to improve prognostication in ccRCC and suggest that metabolic interventions, alongside immunotherapy, might help to manage this disease.
Written by: Jakob Simeth,1 Simon Engelmann,2 Roman Mayr,2 Sebastian Kaelble,2 Florian Weber,3 Renate Pichler,4 Katja Dettmer,5 Peter J. Oefner,5 Marcus Höring,6 Luisa Symeou,7 Katharina Freitag,8 Kilian Wagner,8 Maximilian Burger,2 Wolfgang Herr,8 Marina Kreutz,9 Rainer Spang,10 Gerhard Liebisch,6 Peter J. Siska8
- Chair of Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany; Leibniz Institute for Immunotherapy, Regensburg, Germany.
- Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
- Institute of Pathology, University of Regensburg, Regensburg, Germany.
- Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
- Chair and Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.
- Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.
- Department of Otorhinolaryngology, Regensburg University Hospital, Regensburg, Germany.
- Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany.
- Leibniz Institute for Immunotherapy, Regensburg, Germany; Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany.
- Chair of Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.